Literature DB >> 20694020

Type I natural killer T cells: naturally born for fighting.

Jin-quan Tan1, Wei Xiao, Lan Wang, Yu-ling He.   

Abstract

Type capital I, Ukrainian natural killer T cells (NKT cells), a subset of CD1d-restricted T cells with invariant Valphabeta TCR, are characterized by prompt production of large amounts of Th1 and/or Th2 cytokines upon primary stimulation through the TCR complex. The rapid release of cytokines implies that type capital I, Ukrainian NKT cells may play a critical role in modulating the upcoming immune responses, such as anti-tumor response, protection against infection, and autoimmunity. As a bridge between innate and adaptive immunity, type capital I, Ukrainian NKT cells differentiate and mature upon stimulations to achieve and maintain a homeostasis. Orchestrating with other arms of adaptive immunity, type capital I, Ukrainian NKT cells show strong cytotoxic effects in response to various tumors in a direct and/or indirect manner(s). This review will focus primarily on type capital I, Ukrainian NKT cell development, homeostasis, and effector functions, especially in anti-tumor immunity, and followed by their potential applications in treatment of cancers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20694020      PMCID: PMC4002303          DOI: 10.1038/aps.2010.119

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  92 in total

1.  Intrathymic proliferation wave essential for Valpha14+ natural killer T cell development depends on c-Myc.

Authors:  Marei Dose; Barry P Sleckman; Jin Han; Andrea L Bredemeyer; Albert Bendelac; Fotini Gounari
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-07       Impact factor: 11.205

2.  Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms.

Authors:  Davide Bagnara; Adalberto Ibatici; Mirko Corselli; Nadia Sessarego; Claudya Tenca; Amleto De Santanna; Andrea Mazzarello; Antonio Daga; Renzo Corvò; Giulio De Rossi; Francesco Frassoni; Ermanno Ciccone; Franco Fais
Journal:  Haematologica       Date:  2009-05-19       Impact factor: 9.941

3.  Selective requirement for c-Myc at an early stage of V(alpha)14i NKT cell development.

Authors:  Marcin P Mycko; Isabel Ferrero; Anne Wilson; Wei Jiang; Teresa Bianchi; Andreas Trumpp; H Robson MacDonald
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

Review 4.  MicroRNA control in the immune system: basic principles.

Authors:  Changchun Xiao; Klaus Rajewsky
Journal:  Cell       Date:  2009-01-09       Impact factor: 41.582

5.  Dicer-dependent microRNA pathway controls invariant NKT cell development.

Authors:  Maya Fedeli; Anna Napolitano; Molly Pui Man Wong; Antoine Marcais; Claudia de Lalla; Francesco Colucci; Matthias Merkenschlager; Paolo Dellabona; Giulia Casorati
Journal:  J Immunol       Date:  2009-07-22       Impact factor: 5.422

6.  Immunologic glycosphingolipidomics and NKT cell development in mouse thymus.

Authors:  Yunsen Li; Prakash Thapa; David Hawke; Yuji Kondo; Keiko Furukawa; Koichi Furukawa; Fong-Fu Hsu; Dietlind Adlercreutz; Joel Weadge; Monica M Palcic; Peng G Wang; Steven B Levery; Dapeng Zhou
Journal:  J Proteome Res       Date:  2009-06       Impact factor: 4.466

7.  IFN-gamma-dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model.

Authors:  Daiko Wakita; Kenji Chamoto; Takayuki Ohkuri; Yoshinori Narita; Shigeru Ashino; Kentaro Sumida; Hiroyoshi Nishikawa; Hiroshi Shiku; Yuji Togashi; Hidemitsu Kitamura; Takashi Nishimura
Journal:  Carcinogenesis       Date:  2009-06-09       Impact factor: 4.944

8.  EBV-induced human CD8+ NKT cells suppress tumorigenesis by EBV-associated malignancies.

Authors:  He Yuling; Xiao Ruijing; Li Li; Ji Xiang; Zhou Rui; Wang Yujuan; Zhang Lijun; Du Chunxian; Tan Xinti; Xiao Wei; Chen Lang; Jiang Yanping; Xiong Tao; Wu Mengjun; Xiong Jie; Jin Youxin; Tan Jinquan
Journal:  Cancer Res       Date:  2009-10-06       Impact factor: 12.701

9.  Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.

Authors:  Liping Song; Shahab Asgharzadeh; Jill Salo; Kelly Engell; Hong-wei Wu; Richard Sposto; Tasnim Ara; Ayaka M Silverman; Yves A DeClerck; Robert C Seeger; Leonid S Metelitsa
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

10.  Modulation of NKT cells and Th1/Th2 imbalance after alpha-GalCer treatment in progressive load-trained rats.

Authors:  Wang Ru; Chen Peijie
Journal:  Int J Biol Sci       Date:  2009-05-07       Impact factor: 6.580

View more
  4 in total

Review 1.  Translating Unconventional T Cells and Their Roles in Leukemia Antitumor Immunity.

Authors:  Nilberto Dias de Araújo; Fábio Magalhães Gama; Mateus de Souza Barros; Thaís Lohana Pereira Ribeiro; Fabíola Silva Alves; Lilyane Amorim Xabregas; Andréa Monteiro Tarragô; Adriana Malheiro; Allyson Guimarães Costa
Journal:  J Immunol Res       Date:  2021-01-07       Impact factor: 4.818

2.  Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Attenuates the Development of Angiotensin II-Mediated Abdominal Aortic Aneurysm in Obese ob/ob Mice.

Authors:  Akimichi Saito; Naoki Ishimori; Satoshi Tokuhara; Tsuneaki Homma; Mikito Nishikawa; Kazuya Iwabuchi; Hiroyuki Tsutsui
Journal:  Front Cardiovasc Med       Date:  2021-05-10

3.  Percentages of NKT cells in the tissues of patients with non-small cell lung cancer who underwent surgical treatment.

Authors:  Maria Pyszniak; Paweł Rybojad; Katarzyna Pogoda; Andrzej Jabłonka; Agnieszka Bojarska-Junak; Jacek Tabarkiewicz
Journal:  Kardiochir Torakochirurgia Pol       Date:  2014-03-27

Review 4.  A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies.

Authors:  Małgorzata Waldowska; Agnieszka Bojarska-Junak; Jacek Roliński
Journal:  Cent Eur J Immunol       Date:  2017-08-08       Impact factor: 2.085

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.